Repurposing Diabetes Drugs to Enhance CAR T Cell Therapy for Bladder Cancer
Innovative research shows that diabetes medications like rosiglitazone can boost NECTIN4 expression, making bladder tumors more susceptible to CAR T cell therapy and improving treatment outcomes for resistant bladder cancer cases.
Urothelial carcinoma (UC), a prevalent form of bladder cancer, remains a significant health challenge, causing over 16,000 deaths annually in the United States. Despite advances in treatment, the prognosis for metastatic UC is still poor, with a five-year survival rate between 5% and 10%. A promising development involves repurposing existing medications to improve immunotherapy outcomes.
Currently, enfortumab vedotin (EV), an FDA-approved antibody-drug conjugate, targets NECTIN4, a protein expressed on bladder cancer cells, serving as a frontline treatment for advanced UC. While EV shows a response rate of around 40%, resistance in some patients limits long-term remission and survival benefits. To address this, researchers at UCSF have developed a chimeric antigen receptor (CAR) T cell therapy targeting NECTIN4 and investigated ways to boost its effectiveness.
The team discovered that the PPAR gamma pathway, involved in fat metabolism regulation, influences NECTIN4 expression on tumor cells. Notably, established diabetes drugs like rosiglitazone and pioglitazone activate PPAR gamma, leading to increased NECTIN4 levels. By using these drugs, the researchers could 'prime' the tumor cells, making them more receptive to NECTIN4-specific CAR T cells.
Their studies found that many bladder tumors resistant to EV still retain NECTIN4 expression. Priming tumors with rosiglitazone enhanced the efficacy of CAR T cell therapy in both cell cultures and animal models. This approach effectively turns low-expressing tumors into high-expressing ones, increasing their vulnerability to targeted treatment.
This research provides a basis for combining diabetes medications with immunotherapy to improve outcomes in bladder cancer patients. Continued development and clinical testing of this strategy could expand the therapeutic options for resistant UC cases, potentially leading to longer-lasting remissions and improved survival rates.
Source: Medical Xpress
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Increased Risk of Rare Lymphoma in Breast Cancer Patients with BRCA Mutations and Textured Implants
Women with breast cancer carrying BRCA mutations who receive textured breast implants face a significantly higher risk of developing rare lymphoma, according to new research. The study underscores the importance of genetic testing and personalized healthcare in breast reconstruction decisions.
Access Challenges in Cancer Rehabilitation for Survivors Highlighted by New Research
Despite increasing cancer rehabilitation programs in Australia, many survivors still face barriers to accessing vital post-treatment support. Recent research highlights the need for better funding, infrastructure, and guidelines to improve survivor care and outcomes.
Gut Bacteria Compound Could Slow Alzheimer’s Disease Progression
A compound produced by gut bacteria, known as propionate, shows potential in reducing inflammation and plaque buildup, possibly slowing the progression of Alzheimer’s disease. This research underscores the pivotal role of the gut microbiome in neurodegenerative conditions and opens new therapeutic possibilities.
Premier League: How Kit Colors Influence Team Performance and Visibility
Research shows that team kit colors in the Premier League influence performance, perception, and visibility. From red kits boosting success to the camouflage effects of dull colors, explore how color science affects football outcomes.